Forte Biosciences, Inc. — fact timeline

Forte Biosciences, Inc. shareholders approved Approval of the Amended and Restated 2021 Equity Incentive Plan at the 2026-05-29 meeting.

“4. Approval of the Amended and Restated 2021 Equity Incentive Plan . The Company’s stockholders approved the A&R 2021 Equity Incentive Plan. The votes regarding the proposal were as follows: Votes For Votes Against Abstentions Broker Non-Votes 11,911,879 3,997,050 351,042 1,506,063”

Forte Biosciences, Inc. shareholders approved Advisory Vote on Executive Compensation at the 2026-05-29 meeting.

“3. Advisory Vote on Executive Compensation. The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers for the fiscal year ended December 31, 2025. The votes regarding the proposal were as follows: Votes For Votes Against Abstentions Broker Non-Votes 12,143,153 3,764,729 352,089 1,506,063”

Forte Biosciences, Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2026-05-29 meeting.

“2. Ratification of Appointment of Independent Registered Public Accounting Firm. The appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified based on the following results of voting: Votes For Votes Against Abstentions Broker Non-Votes 17,722,893 3,182 39,959 0”

Forte Biosciences, Inc. shareholders approved Election of Class III Directors at the 2026-05-29 meeting.

“1. Election of Class III Directors. The following nominees were elected to serve as Class III directors, each to hold office until the Company’s 2029 annual meeting of stockholders or until his respective successor has been duly elected and qualified or his or her earlier resignation or removal: Nominee Votes For Votes Withheld Broker Non-Votes Steven Kornfeld 12,286,043 3,973,928 1,506,063 Scott Brun, M.D. 12,958,889 3,301,082 1,506,063 Paul A. Wagner, Ph.D. 16,027,110 232,861 1,506,063”

Forte Biosciences, Inc. reported the quarter ended March 31, 2026 results: net income Net loss per share - basic and diluted $ (1.24 ), EPS $(1.24).

“Forte Biosciences, Inc. issued a press release reporting its financial results for the quarter ended March 31, 2026.”

Forte Biosciences, Inc. entered into Underwriting Agreement with Guggenheim Securities, LLC valued at approximately $150 million (effective 2026-04-08).

“On April 8, 2026, Forte Biosciences, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Guggenheim Securities, LLC as representative (the “Representative”) of the several underwriters named therein (collectively, the “Underwriters”), relating to the issuance and sale in a public offering (the “Offering”) of 5,709,936 shares of the Company’s common stock, par value $0.001 per share, at a price to the public of $26.27 per share (the “Shares”).”

Forte Biosciences, Inc. reported the year ended December 31, 2025 results: net income $(69,375) thousand, EPS $(4.71).

“Interest income 2,715 1,314 Other expense, net (396 ) (190 ) Total other income, net 2,319 1,124 Net loss before taxes (68,338 ) (35,478 ) Income tax expense 1,037 — Net loss $ (69,375 ) $ (35,478 ) Per share information: Net loss per share - basic and diluted $ (4.71 ) $ (12.17 ) Weighted average share, and pre-funded warrants outstanding, basic and diluted”

Shiv Kapoor was appointed as Director at Forte Biosciences, Inc..

“On September 17, 2024, the Board of Directors (the “Board) of Forte Biosciences, Inc. (the “Company”), upon recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating Committee”), appointed Richard Vincent and Shiv Kapoor to the Board to fill the vacancies on the Board created by the resignations of each of Donald A. Williams and Lawrence Eichenfield, each of whom had tendered their resignation from the Board as detailed below, in each case effective September 17, 2024.”

Richard Vincent was appointed as Director at Forte Biosciences, Inc..

“On September 17, 2024, the Board of Directors (the “Board) of Forte Biosciences, Inc. (the “Company”), upon recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating Committee”), appointed Richard Vincent and Shiv Kapoor to the Board to fill the vacancies on the Board created by the resignations of each of Donald A. Williams and Lawrence Eichenfield, each of whom had tendered their resignation from the Board as detailed below, in each case effective September 17, 2024.”

Lawrence Eichenfield resigned as Director at Forte Biosciences, Inc..

“On September 17, 2024, the Board of Directors (the “Board) of Forte Biosciences, Inc. (the “Company”), upon recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating Committee”), appointed Richard Vincent and Shiv Kapoor to the Board to fill the vacancies on the Board created by the resignations of each of Donald A. Williams and Lawrence Eichenfield, each of whom had tendered their resignation from the Board as detailed below, in each case effective September 17, 2024.”

Donald A. Williams resigned as Director at Forte Biosciences, Inc..

“On September 17, 2024, the Board of Directors (the “Board) of Forte Biosciences, Inc. (the “Company”), upon recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating Committee”), appointed Richard Vincent and Shiv Kapoor to the Board to fill the vacancies on the Board created by the resignations of each of Donald A. Williams and Lawrence Eichenfield, each of whom had tendered their resignation from the Board as detailed below, in each case effective September 17, 2024.”

Forte Biosciences, Inc. reported the quarter ended March 31, 2024 results: net income $(7,420 ), EPS $(0.16 ).

“On May 13, 2024, Forte Biosciences, Inc. issued a press release reporting its financial results for the quarter ended March 31, 2024.”

Forte Biosciences, Inc. reported the fourth quarter and fiscal year ended December 31, 2023 results: net income $ (31,476 ), EPS $ (1.00 ).

“On March 18, 2024, Forte Biosciences, Inc. issued a press release reporting its financial results for the fourth quarter and fiscal year ended December 31, 2023.”

Forte Biosciences, Inc. shareholders approved Advisory vote on the frequency of future advisory votes on the compensation of the Company's named executive officers at the 2023-09-19 meeting.

“The highest number of votes was cast in favor of holding an advisory vote on the compensation of the Company’s named executive officers every year.”

Forte Biosciences, Inc. engaged KPMG LLP as its auditor.

“On December 4, 2023, the Audit Committee approved the appointment of KPMG LLP ("KPMG") as the Company's new independent registered public accounting firm for the fiscal year ending December 31, 2023.”

Forte Biosciences, Inc. shareholders rejected Advisory Vote on Shareholder Proposal to Remove the Company’s Preferred Stock Rights Agreement at the 2023-09-19 meeting.

“7. Advisory Vote on Shareholder Proposal to Remove the Company’s Preferred Stock Rights Agreement. The Company’s stockholders voted against the removal of the Company’s Preferred Stock Rights Agreement. The votes regarding the proposal were as follows: Votes For Votes Against Abstentions 11,096,793 14,525,586 1,871,743”

Forte Biosciences, Inc. shareholders rejected Shareholder Proposal to Amend the Amended and Restated Bylaws at the 2023-09-19 meeting.

“6. Shareholder Proposal to Amend the Amended and Restated Bylaws. The Company’s stockholders voted against the amendment of the Company’s Amended and Restated Bylaws. The votes regarding the proposal were as follows: Votes For Votes Against Abstentions 10,813,380 14,810,177 1,870,565”

Forte Biosciences, Inc. shareholders approved Approval of the Amended and Restated 2021 Equity Incentive Plan at the 2023-09-19 meeting.

“5. Approval of the Amended and Restated 2021 Equity Incentive Plan. The Company’s stockholders approved the adoption of the Amended and Restated 2021 Equity Incentive Plan. The votes regarding the proposal were as follows: Votes For Votes Against Abstentions 16,838,182 8,502,806 2,103,978”

Forte Biosciences, Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2023-09-19 meeting.

“4. Ratification of Appointment of Independent Registered Public Accounting Firm. The appointment of Mayer Hoffman McCann P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 was ratified based on the following results of voting: Votes For Votes Against Abstentions 17,303,222 3,776,436 6,502,444”

Forte Biosciences, Inc. shareholders rejected Advisory Vote on Executive Compensation at the 2023-09-19 meeting.

“2. Advisory Vote on Executive Compensation. The Company’s stockholders advised that they were not in favor of the named executive officers’ compensation for 2022 as disclosed in the proxy statement. The votes regarding the proposal were as follows: Votes For Votes Against Abstentions 9,907,983 11,751,111 5,835,028”

Forte Biosciences, Inc. shareholders approved Election of Class III Directors at the 2023-09-19 meeting.

“1. Election of Class III Directors. Lawrence Eichenfield, M.D. and Paul A. Wagner, Ph.D. were elected to serve as Class III directors, to hold office until the Company’s 2026 annual meeting of stockholders or until his respective successor is duly elected and qualified. The final votes for each nominee to serve as a Class III director are set forth below: Nominee Votes For Votes Withheld Lawrence Eichenfield, M.D. 16,396,500 11,097,526 Paul A. Wagner, Ph.D. 16,831,738 10,662,288 Chris McIntyre 10,627,041 16,348,276 Michael G. Hacke 11,064,021 15,911,296”

Forte Biosciences, Inc. shareholders rejected Advisory Vote on Shareholder Proposal to Remove the Company’s Preferred Stock Rights Agreement at the 2023-09-19 meeting.

“7. Advisory Vote on Shareholder Proposal to Remove the Company’s Preferred Stock Rights Agreement. The estimated preliminary votes for the advisory proposal to remove the preferred stock rights agreement are set forth below. Votes For Votes Against Abstentions 11,096,793 14,525,586 1,871,743”

Forte Biosciences, Inc. shareholders rejected Shareholder Proposal to Amend the Amended and Restated Bylaws at the 2023-09-19 meeting.

“6. Shareholder Proposal to Amend the Amended and Restated Bylaws. The estimated preliminary votes for the shareholder proposal to amend the Amended and Restated Bylaws are set forth below. Votes For Votes Against Abstentions 10,813,380 14,810,177 1,870,565”

Forte Biosciences, Inc. shareholders approved Approval of the Amended and Restated 2021 Equity Incentive Plan at the 2023-09-19 meeting.

“5. Approval of the Amended and Restated 2021 Equity Incentive Plan. The estimated preliminary votes for the adoption of the Amended and Restated 2021 Equity Incentive Plan are set forth below. Votes For Votes Against Abstentions 16,838,182 8,502,806 2,103,978”

Forte Biosciences, Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2023-09-19 meeting.

“4. Ratification of Appointment of Independent Registered Public Accounting Firm. The estimated preliminary votes for the appointment of Mayer Hoffman McCann P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 are set forth below. Votes For Votes Against Abstentions 17,303,222 3,776,436 6,502,444”

Forte Biosciences, Inc. shareholders voted on Frequency of Advisory Vote on Executive Compensation at the 2023-09-19 meeting.

“3. Frequency of Advisory Vote on Executive Compensation. The estimated preliminary votes for the frequency of future advisory votes on executive compensation are set forth below. One Year Two Years Three Years Abstentions 13,958,000 35,449 9,869,970 3,630,703”

Forte Biosciences, Inc. shareholders rejected Advisory Vote on Executive Compensation at the 2023-09-19 meeting.

“2. Advisory Vote on Executive Compensation. The estimated preliminary votes for the advisory vote on executive compensation are set forth below. Votes For Votes Against Abstentions 9,907,983 11,751,111 5,835,028”

Forte Biosciences, Inc. shareholders voted on Election of Class III Directors at the 2023-09-19 meeting.

“1. Election of Class III Directors. The estimated preliminary votes for each nominee are set forth below. The two nominees with the most votes in favor will be elected to the board after certification of the final results by the Inspector of Election: Nominee Votes For Votes Withheld Lawrence Eichenfield, M.D. 16,396,500 11,097,526 Paul A. Wagner, Ph.D. 16,831,738 10,662,288 Chris McIntyre 10,627,041 16,348,276 Michael G. Hacke 11,064,021 15,911,296”

Forte Biosciences, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“September 14, 2023, Forte Biosciences, Inc. (the “Company”) received a written notice (the “Notice”) from the Nasdaq Listing Qualifications staff of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last 30 consecutive business days, the minimum bid price of the Company’s common stock had been below the $1.00 per share minimum requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar”

Forte Biosciences, Inc. entered into Securities Purchase Agreement with certain qualified institutional buyers, institutional accredited investors and certain executive officers, senior management, and members of the Board of Directors of the Company valued at approximately $25 million (effective 2023-07-28).

“On July 28, 2023, Forte Biosciences, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) for a private placement (the “Private Placement”) with certain qualified institutional buyers, institutional accredited investors and certain executive officers, senior management, and members of the Board of Directors of the Company (the “Board”) (each, a “Purchaser” and collectively, the “Purchasers”).”

Forte Biosciences, Inc. amended Preferred Stock Rights Agreement, as amended by Amendment No. 1 to the Rights Agreement with Computershare Trust Company, N.A. valued at Extends expiration of Rights to 5:00 p.m., New York City time, on July 12, 2024 (effective 2023-06-26).

“On June 26, 2023, the Company entered into Amendment No. 1 to the Rights Agreement between the Company and Computershare Trust Company, N.A., as rights agent (the “Amendment”), which amends the Rights Agreement.”

Forte Biosciences, Inc. reported the fourth quarter and fiscal year ended December 31, 2022 results: net income Net losses were $13.9 million and $21.7 million, and net losses per share were ($0.80) and ($1.55) for the years ended D, EPS net losses per share were ($0.80) and ($1.55) for the years ended December 31, 2022 and 2021, respectively..

“On March 31, 2023, Forte Biosciences, Inc. issued a press release reporting its financial results for the fourth quarter and fiscal year ended December 31, 2022.”

Forte Biosciences, Inc.: Amended and restated bylaws to revise director nomination procedures, stockholder meeting procedures, and make ministerial changes to conform to Delaware law (effective 2023-02-07).

“On February 7, 2023, the Board of Directors (the “Board”) of Forte Biosciences, Inc. (the “Company”), acting upon the recommendation of the Nominating and Corporate Governance Committee of the Board, amended and restated the Company’s amended and restated bylaws, effective immediately.”

Patricia Walker resigned as Director at Forte Biosciences, Inc..

“On January 6, 2023, Patricia Walker, M.D., Ph.D. notified Forte Biosciences, Inc. (the “Company”) of her resignation as a member of the Board of Directors (the “Board”) of the Company and from all committees of the Board on which she served, in each case effective as of January 6, 2023.”

David Gryska was appointed as Director at Forte Biosciences, Inc..

“On January 10, 2023, the Board of Directors (the “Board) of the Company, upon recommendation of the Nominating and Governance Committee of the Board, appointed David Gryska, M.B.A. to the Board to fill a vacancy on the Board, effective January 10, 2023.”

Forte Biosciences, Inc. reported the quarter ended September 30, 2022 results: EPS ($0.18).

“Net losses per share were ($0.18) and ($0.54) for the three months ended September 30, 2022 and 2021, and ($0.56) and ($1.34) for the nine months ended September 30, 2022 and 2021, respectively.”

Scott Brun was appointed as Director at Forte Biosciences, Inc..

“On November 10, 2022, the Board of Directors (the “Board) of the Company, upon recommendation of the Nominating and Governance Committee of the Board, appointed Scott Brun, M.D. to the Board, effective November 10, 2022.”

Paul A. Wagner changed role as President at Forte Biosciences, Inc..

“the title of President of the Company transitioned from Paul A. Wagner, Ph.D. to Dr. Chen, provided that Dr. Wagner will continue to serve as the Company’s Chief Executive Officer and a member of the Board.”

Hubert C. Chen was appointed as President and Chief Scientific Officer at Forte Biosciences, Inc..

“On June 5, 2022, the Board of Directors (“Board”) of Forte Biosciences, Inc. (the “Company”) appointed Hubert C. Chen, M.D. to serve as President and Chief Scientific Officer of the Company, effective June 7, 2022.”

Stephen K. Doberstein was appointed as Director at Forte Biosciences, Inc..

“Appointment of Director On May 12, 2022, the Board of Directors (the “Board) of Forte Biosciences, Inc. (the “Company”), upon recommendation of the Nominating and Governance Committee of the Board, appointed Stephen K. Doberstein, Ph.D. to the Board, effective May 12, 2022.”

Barbara K. Finck, M.D. was appointed as Director at Forte Biosciences, Inc..

“appointed Barbara K. Finck, M.D. to the Board, effective March 16, 2022.”